Aortic stiffness is an established vascular biomarker that independently predicts cardiovascular risk [4-6]. The concept behind the use of this biomarker, which has been endorsed by Scientific Societies [7,8], is that early vascular aging rather than chronological aging can offer better risk prediction. Even estimated Carotid Femoral Pulse Wave Velocity (cfPWV) predicts outcomes independent of the Framingham Risk Score and peripheral blood pressure as we recently shown in a secondary analysis of the systolic blood pressure intervention trial (SPRINT) [9]. The aim of this review article was to summarize current evidence regarding the effects of MAb on arterial stiffness. 2. METHODS For purpose of this review, we explored one full-text database (Google-Scholar) and two bibliographic databases [PubMed, Scopus] using two methods: (1) searching for keywords using variations of "arterial stiffness'' , "aortic stiffness'' , "arterial elasticity", "arterial properties'' , "arteriosclerosis'' and "PWV, " and "monoclonal antibody therapy'' , "monoclonal antibody chemotherapy'' , "chemotherapy''; (2) searching for keywords using variations of specific chemotherapy Mab agents and variations of "arterial stiffness'' as above. Our search included all publications published until the writing of this manuscript